Ebola intelligence brief.
Confirmed WHO facts
WHO's daily table, accessed 9 September, reports 6,778 confirmed cases and 3,269 confirmed deaths across the Democratic Republic of the Congo, Uganda and France. The total uses Democratic Republic of the Congo data through 7 September, Uganda data through 21 July and France data through 6 July. Compared with the preceding published table using Democratic Republic of the Congo data through 6 September, this is an increase of 71 confirmed cases and 41 confirmed deaths. The Democratic Republic of the Congo accounts for 6,757 cases and 3,267 deaths; the table reports 1,609 recoveries across the three countries. Disease Outbreak News 616 reports that the outbreak expanded from 54 to 60 health zones across six provinces between 14 and 26 August. WHO's emergency vaccine guidance, published 1 September, concludes that available evidence remains insufficient to determine whether Ervebo provides clinically meaningful protection against Bundibugyo virus in humans and recommends use only within research protocols, including rapid generation of robust efficacy evidence through a ring randomized controlled trial. WHO says proven outbreak-control measures must continue and unknown efficacy must be communicated clearly.
WHO states that part of the rise since 14 August likely reflects expanded surveillance, stronger laboratory testing, improved diagnostic capacity and periodic reconciliation of reporting backlogs, while the sustained increase also reflects continued transmission and geographic expansion. The daily graphic combines different country cut-off dates, and reported figures may be revised retrospectively; totals therefore do not provide a final or real-time measure of outbreak burden. WHO's vaccine guidance addresses off-label use under authorised research protocols; it is not evidence of established protection against Bundibugyo virus and is not personal medical advice. No vaccine or specific treatment is currently approved for Bundibugyo virus disease.
Vision Biotechnology response lens
- Maintain validated molecular and referral workflows with trained personnel, biosafety controls, documented quality systems, external quality assurance and clear escalation criteria.
- Route suspected-case testing, confirmation and reporting only through authorised national and international public-health pathways.
- Plan surge stock, controls, specimen transport, cold-chain interfaces, lot traceability and continuity around authority-led scenarios and end-to-end visibility of supply gaps.
- Treat localisation as a controlled capacity-building programme: methods comparison, training, change control, regulatory readiness and supply resilience must accompany equipment deployment.